Fady Sayegh Selected Research

moexipril (Perdix)

1/2005	Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients.
2/2002	Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fady Sayegh Research Topics

Disease

2	Essential Hypertension 01/2005 - 02/2002
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2005 - 02/2002

Drug/Important Bio-Agent (IBA)

2	moexipril (Perdix)FDA LinkGeneric 01/2005 - 02/2002
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2005 - 02/2002